Novo Nordisk's new weight loss oral medication is applying for clinical efficacy or surpassing smeglutide in China
Ty奇葩罗牛山831
发表于 2024-4-11 19:03:29
1231
0
0
On April 10th, the official website of the Drug Evaluation Center (CDE) of the National Medical Products Administration of China announced that the clinical trial application for the Class 1 new oral weight loss drug Amycretin tablets submitted by Novo Nordisk has been officially accepted.
Amycretin is another heavyweight loss therapy developed by Novo Nordisk, following Smegglutide. It is a novel oral GLP-1 receptor and Amylin receptor long-acting co agonist. A small Phase 1 clinical study recently released by Novo Nordisk showed that after 12 weeks of treatment with the drug, patients experienced an average weight loss of 13.1%, surpassing the weight loss efficacy of the old version of the semaglutide medication taken in the same cycle by 6%.
Novo Nordisk stated at last month's annual investor meeting that the mid-term trial of the drug will begin in the second half of this year and is expected to yield results in early 2026.
After the huge success of GLP-1 drugs, several companies are currently developing other promising new weight loss therapies, such as Amycretin, which targets amylin in the pancreas, which affects hunger. Similar to GLP-1, amylin can also slow down gastric emptying and promote satiety.
In addition to Novo Nordisk, another pharmaceutical company, Zealand, also has two pancreatic amyloid therapies under development. The company is also collaborating with German pharmaceutical company Boehringer Ingelheim to develop weight loss drugs.
Van Lanschot Kempen, a Dutch securities firm, believes that amyloid analogues are a "differentiated asset" in the weight-loss drug industry and can provide therapies tailored to different mechanisms.
On the other hand, oral versions of weight loss drugs have more advantages from the perspective of improving patient compliance. Novo Nordisk already has advantages in the development of oral therapies. In January this year, Novo Nordisk Megglutide Tablets was approved by the National Drug Administration (NMPA) for marketing. It is the first oral GLP-1 (glucagon like peptide-1) receptor agonist approved for marketing in China, which is used to treat adult type 2 diabetes.
At present, the oral preparation of Smegglutide for weight loss indications has entered phase 3 clinical trials in China, evaluating the efficacy and safety of 50mg oral preparation once daily in overweight or obese adults in China.
It is worth noting that the patent for Smegglutide compound in China will expire in 2026. On April 3rd, the official website of the Drug Evaluation Center of the National Medical Products Administration showed that Hangzhou Jiuyuan Genetic Engineering Co., Ltd.'s application for the listing of "Jiyoutai" injection of Smegglutide was accepted, making it the first Smegglutide biosimilar drug in mainland China to apply for listing.
In this context, Novo Nordisk's clinical application for the new generation GLP-1 class of drugs in China will help the company maintain its market advantage even after the expiration of the patent for Smegglutide.
Novo Nordisk also expects that the Wegovy injection, which is used for weight loss indications, is expected to be approved for sale in mainland China this year.
With Smegglutide, the market value of Novo Nordisk has exceeded $560 billion, surpassing Tesla's market value. The reason why GLP-1 drugs have ignited the capital market is because of their broader application prospects.
According to the latest research results published in the New England Journal of Medicine (NEJM) last Saturday, such hypoglycemic drugs can also reduce the risk of heart failure of diabetes patients with obesity related ejection fraction retention.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
- Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
- The Battle of Weight Loss Drugs Begins: Smegglutide's Obesity Indications Approved in China
- "Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
- Yizi International expands its business in China and adds equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
- China International Import Expo opens listening mode, 'all students' look forward to the prospects of the Chinese market
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Weight reducing version of semaglutide officially launched in China
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏